Georgia Life Sciences Partners with U.S. Chamber Foundation to Bring Real-World Innovation to Georgia Classrooms

Georgia Life Sciences Partners with U.S. Chamber Foundation to Bring Real-World Innovation to Georgia Classrooms

60 + high school students tackle real industry challenges through national EPIC program


July 7, 2025

ATLANTA – Georgia Life Sciences (GLS) has successfully completed its first collaboration with the U.S. Chamber of Commerce Foundation’s Employer Provided Innovation Challenges (EPIC) program, bringing hands-on, real-world learning into Georgia classrooms and spotlighting the state’s growing leadership in workforce innovation.

 

Through this groundbreaking initiative, GLS developed and piloted three challenge-based projects designed to spark student interest in the life sciences:

  • Navigating Medical Device Regulatory Pathways
  • Innovative Solutions in Food Production
  • Automated Biomanufacturing

 

Over 60 high school students across the state formed 12 teams to tackle these challenges, working directly with industry volunteer mentors to co-design creative solutions. All participants earned credentials for their work, demonstrating not only career awareness but real-world readiness for Georgia’s growing bioscience sector.

 

One standout team—composed of homeschool students from the Georgia Black Home Educators Network (GBHEN), sponsored by Blue Heron Urban Farm and Sanctuary—was selected to present at the EPIC National Convening on June 24 in Washington, D.C., hosted at the U.S. Chamber of Commerce. The team shared their innovations in sustainable food production, highlighting the role of student ingenuity in solving global challenges.

 

“This program gave students a window into the real world of biotech, medical devices, and agtech,” said Dr. Phil Gibson, Executive Director for the Georgia Life Sciences Institute. “It also gave our industry partners a powerful new way to engage with the future workforce—and even shape it.”

 

EPIC, launched by the U.S. Chamber Foundation, is redefining the connection between business innovation and workforce development by giving students access to real problems, real collaboration, and real career exposure.

 

This effort is part of Georgia Life Sciences’ broader mission to build a sustainable talent pipeline in the life sciences—from classroom to career. Through initiatives like this partnership with the Us Chamber Foundation and the public/private partnership with Georgia’s Department of Education, the Biotech Teacher Training Initiative (BTTI), GLS provides immersive, standards-aligned professional development for Georgia educators to bring modern biotech concepts and techniques into biology, chemistry, agriculture, and environmental science classrooms statewide.

 

Why It Matters

As Georgia’s life sciences industry continues to grow, workforce demand is outpacing supply. Programs like EPIC play a vital role in bridging that gap by increasing industry awareness early in the pipeline. Building student familiarity with bioscience careers—and connecting them with real industry mentors—is essential to strengthening Georgia’s long-term competitiveness in biotechnology, biomanufacturing, and global health innovation.

 

About Georgia Life Sciences

Georgia Life Sciences is the statewide association advancing the life sciences ecosystem through policy advocacy, economic development, workforce initiatives, and industry-led innovation. From breakthrough biomanufacturing to patient access, GLS is committed to making Georgia a leader in global health and biotechnology.

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS